Some Pharmaceutical Benefits Scheme (PBS) subsidised medicines need written authority approval from us before they can be prescribed.
Some PBS medicines need written authority approval due to their clinical use or other special features.
This includes a number of Complex Authority Required (CAR) drugs.
These medicines will not be PBS subsidised without authority approval. Retrospective approval cannot be granted.
Applying for authority approval
Health Professional Online Services (HPOS)
To apply for approval to prescribe a written authority required drug through HPOS, you must upload the completed and signed PBS authority application form, supporting documents and authority prescription form(s).
When approved, prescribers can access the authority approval number through HPOS and must record it on the authority prescription form. Prescribers should also record the item code on the authority prescription form.
To apply for approval to prescribe a written authority required drug via mail, you must post the completed and signed PBS authority application form, supporting documents and authority prescription form(s).
When approved, the authority prescription form is stamped with CAR approval and returned by mail to the provider or patient as indicated on the form.
Where authority applications for balance of supply or continuing treatment can be made by phone, you must call the PBS Complex Drugs Programs enquiry line.
When approved, prescribers must record the authority approval number provided by us on the authority prescription form. Phone authority approval numbers start with Z, CARZ or TRZZ and are followed by 4 digits and 2 letters. For example, Z1234AB or CARZ1234AB or TRZZ1234AB.
Hospital authority form
To prescribe CAR Highly Specialised Drugs (HSDs) in a non-reform public hospital approved to supply HSDs, prescribers must use the Non PBS Reform Public Hospital Highly Specialised Drugs and Trastuzumab Only Authority Prescription Form (PB054).
To prescribe CAR HSDs in a public hospital participating in the pharmaceutical reforms, the prescriber can use the Public Hospital Prescription form.
To prescribe CAR HSDs in a private hospital, prescribers can use their own personalised PBS prescription pads.
Drug, program or condition
The PBS subsidises pasireotide and pegvisomant for patients with acromegaly.
The PBS subsidises medicines for eligible patients with Alzheimer's disease.
The PBS subsidises biological agents for patients with active ankylosing spondylitis.
Arthritis - juvenile idiopathic arthritis
The PBS subsidises biological disease-modifying antirheumatic drugs for patients with severe active juvenile idiopathic arthritis.
Arthritis - psoriatic arthritis
The PBS subsidises biological agents for patients with severe active psoriatic arthritis.
Arthritis - rheumatoid arthritis
The PBS subsidises biological agents for patients with severe active rheumatoid arthritis.
Arthritis - systemic juvenile idiopathic arthritis
The PBS subsidises tocilizumab for patients with systemic juvenile idiopathic arthritis.
Asthma - severe allergic asthma - adolescent and adult patients
The PBS subsidises omalizumab for patients aged 12 years or older with uncontrolled severe allergic asthma.
Asthma - severe allergic asthma - paediatric patient
The PBS subsidises omalizumab for paediatric patients with uncontrolled severe allergic asthma.
Asthma – severe eosinophilic asthma
The PBS subsidises mepolizumab for patients with uncontrolled severe eosinophilic asthma.
Atypical haemolytic uraemic syndrome
The PBS subsidises eculizumab for patients with atypical haemolytic uraemic syndrome (aHUS).
Basal cell carcinoma - metastatic or locally advanced
The PBS subsidises sonidegib and vismodegib for patients with metastatic or locally advanced basal cell carcinoma (BCC).
Breast cancer - early breast cancer
The PBS subsidises trastuzumab for patients with human epidermal growth factor receptor 2 (HER2) positive early breast cancer or HER2 positive locally advanced breast cancer.
Breast cancer - metastatic breast cancer
The PBS subsidises lapatinib, pertuzumab, trastuzumab and trastuzumab emtansine for patients with metastatic breast cancer.
The PBS subsidises sapropterin for patients with tetrahydrobiopterin (BH4) deficiency.
Crohn's disease - adult patient
The PBS subsidises biological agents for adult patients with severe Crohn's disease.
Crohn's disease - fistulising Crohn's disease
The PBS subsidises tumour necrosis factor alfa antagonists for patients with complex refractory fistulising Crohn's disease.
Crohn's disease - paediatric patient
The PBS subsidises TNF alfa antagonists for paediatric patients with Crohn's disease.
The PBS subsidises ivacaftor for patients aged 2 years or older with cystic fibrosis.
Eye - diabetic macular oedema
The PBS subsidises aflibercept, dexamethasone intravitreal implant and ranibizumab for patients with diabetic macular oedema (DMO).
Eye - retinal vein occlusion
The PBS subsidises aflibercept and ranibizumab for patients with branched retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) with macular oedema.
Eye - subfoveal choroidal neovascularisation
The PBS subsidises aflibercept, ranibizumab and verteporfin for patients with subfoveal choroidal neovascularisation.
Familial homozygous hypercholesterolaemia
The PBS subsidises evolocumab for patients with familial homozygous hypercholesterolaemia.
Gastric cancer - metastatic stage IV HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction
The PBS subsidises trastuzumab for patients with metastatic stage IV HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction.
Gastrointestinal stromal tumour (GIST) - adjuvant
The PBS subsidises imatinib mesilate for patients with resected primary gastrointestinal stromal tumour (GIST) with high risk of recurrence.
Gastrointestinal stromal tumour (GIST) - metastatic or unresectable
Imatinib - the PBS subsidises imatinib mesilate for patients with metastatic or unresectable malignant gastrointestinal stromal tumour (GIST).
Gastrointestinal stromal tumour (GIST) - sunitinib malate
The PBS subsidises sunitinib malate for patients with a metastatic or unresectable malignant gastrointestinal stromal tumour (GIST).
Granulomatosis - severe active granulomatosis with polyangiitis or severe active microscopic polyangiitis
The PBS subsidises rituximab for patients with severe active granulomatosis with polyangiitis or severe active microscopic polyangiitis.
Growth Hormone Program
The Growth Hormone Program provides subsidised PBS treatment to eligible children under a number of categories.
The PBS subsidises adalimumab for patients with moderate to severe hidradenitis suppurativa (HS).
Idiopathic pulmonary fibrosis
The PBS subsidises nintedanib and pirfenidone for patients with idiopathic pulmonary fibrosis (IPF).
Idiopathic thrombocytopenic purpura
The PBS subsidises eltrombopag and romiplostim for patients with severe chronic immune idiopathic thrombocytopenic purpura.
Leukaemia - acute lymphoblastic leukaemia
The PBS subsidises blinatumomab, dasatinib, imatinib mesilate and ponatinib for patients with acute lymphoblastic leukaemia (ALL).
Leukaemia - chronic lymphocytic leukaemia
The PBS subsidises idelalisib and obinutuzumab for patients with chronic lymphocytic leukaemia (CLL).
Leukaemia - chronic myeloid leukaemia
The PBS subsidises tyrosine kinase inhibitor (TKI) agents for patients with chronic myeloid leukaemia (CML).
Lymphoma - cutaneous T-cell lymphoma
The PBS subsidises vorinostat for patients with cutaneous T-cell lymphoma (CTCL).
Lymphoma - Hodgkin lymphoma
The PBS subsidises brentuximab vedotin for patients with relapsed or refractory Hodgkin lymphoma.
Lymphoma - refractory follicular B-cell non-Hodgkin’s lymphoma
The PBS subsidises idelalisib for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.
Lymphoma - small lymphocytic lymphoma
The PBS subsidises idelalisib for patients with small lymphocytic lymphoma (SLL).
Lymphoma - systemic anaplastic large cell lymphoma
The PBS subsidises brentuximab vedotin for eligible patients with systemic anaplastic large cell lymphoma.
Multiple myeloma - bortezomib, lenalidomide and pomalidomide
The PBS subsidises bortezomib, lenalidomide and pomalidomide for patients with multiple myeloma.
Myelodysplastic syndrome - azacitidine
The PBS subsidises azacitidine for patients with myelodysplastic syndrome, chronic myelomonocytic leukaemia or acute myeloid leukaemia.
Myelodysplastic syndrome - lenalidomide
The PBS subsidises lenalidomide for patients with myelodysplastic syndrome classified as low risk or Intermediate-1.
The PBS subsidises ruxolitinib for patients with myelofibrosis.
The PBS subsidises modafinil and armodafinil for patients with narcolepsy.
Non-small cell lung cancer
The PBS subsidises crizotinib for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC).
Psoriasis - severe chronic plaque psoriasis - adult patients
The PBS subsidises biological agents for adult patients with severe chronic plaque psoriasis.
Psoriasis - severe chronic plaque psoriasis - patients under 18 years
The PBS subsidises etanercept for patients under 18 years with severe chronic plaque psoriasis.
Pulmonary hypertension - chronic thromboembolic pulmonary hypertension
The PBS subsidises riociguat for patients with chronic thromboembolic pulmonary hypertension.
Pulmonary hypertension - arterial
The PBS subsidises a range of medicines for patients with primary pulmonary and pulmonary arterial hypertension.
The PBS subsidises imatinib mesilate for patients with rare diseases.
The PBS subsidises adalimumab, infliximab and vedolizumab (adults only) for patients with moderate to severe ulcerative colitis.
Urticaria - severe chronic spontaneous urticaria
The PBS subsidises omalizumab for patients with severe chronic spontaneous urticaria.